A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Details: By ClinicalTrials.gov; Category: Joint Diseases; Jul 17, 2007

Condition: Rheumatoid Arthritis
Intervention: Drug: rituximab [MabThera/Rituxan]
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified July 2011

Last Updated: 17 July 2007

Joint Diseases Clinical Trials

A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Home

News

Specialists

Joint Diseases Clinical Trials

A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

TPL_FOLLOW_US

Home

News

Specialists